For research use only. Not for therapeutic Use.
Mavacamten（Cat No.:I007910）is a selective cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM). By targeting excessive myosin activity, it reduces abnormal heart muscle contraction, relieving symptoms such as shortness of breath, chest pain, and fatigue. Mavacamten works by improving left ventricular outflow tract obstruction, enhancing cardiac function, and overall quality of life in HCM patients. This innovative therapy addresses the underlying cause of HCM and offers a promising treatment option for individuals with obstructive and non-obstructive forms of the condition, leading to improved cardiac performance and patient outcomes.
| Catalog Number | I007910 |
| CAS Number | 1642288-47-8 |
| Synonyms | SAR-439152; SAR 439152; SAR439152; MYK-461; MYK 461; MYK461; Mavacamten.;(S)-3-isopropyl-6-((1-phenylethyl)amino)pyrimidine-2,4(1H,3H)-dione |
| Molecular Formula | C15H19N3O2 |
| Purity | 99% |
| Target | MYO |
| Target Protein | |
| Solubility | Soluble in DMSO |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | IC50: 490 nM (bovine cardiac), 711 nM (human cardiac) |
| IUPAC Name | 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione |
| InChI | InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1 |
| InChIKey | RLCLASQCAPXVLM-NSHDSACASA-N |
| SMILES | C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C |
| Reference | </br>1: Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, Henze M, Kawas R, Oslob JD, Rodriguez HM, Song Y, Wan W, Leinwand LA, Spudich JA, McDowell RS, Seidman JG, Seidman CE. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016 Feb 5;351(6273):617-21. doi: 10.1126/science.aad3456. PubMed PMID: 26912705; PubMed Central PMCID: PMC4784435. |
